Peptide vaccine shows evidence of immunological, clinical activity in children with gliomas

April 3, 2012

Peptide vaccination in children with gliomas was well tolerated with evidence of immunological and clinical responses, but some children experienced periods of immunological pseudoprogression, where tumors appeared larger than they actually were, according to results presented at the AACR Annual Meeting 2012, held here March 31 – April 4.

“We’ve found that the is tolerated well with limited systemic toxicity, but we’ve also observed that there are some patients who have immunological responses to the vaccine target in the brain that can cause swelling and transient worsening, and subsequently, some of those children can have very favorable responses,” said Ian F. Pollack, M.D., Walter Dandy professor of neurological surgery and vice chairman for academic affairs in the department of neurological surgery at the University of Pittsburgh School of Medicine in Pittsburgh, Pa. “We’ve also demonstrated immunological responses in the majority of the kids.”

In the pilot study, Pollack, who is also chief of pediatric neurosurgery at Children’s Hospital of Pittsburgh and co-director of the University of Pittsburgh Cancer Institute Brain Program in Pittsburgh, Pa., and colleagues enrolled 27 children, including 16 with newly diagnosed brain stem gliomas, five with newly diagnosed cerebral high-grade gliomas and six with recurrent gliomas.

Researchers assigned HLA-A2–positive children to subcutaneous vaccinations with for glioma-associated antigen (GAA) epitopes emulsified in Montanide-ISA-51 every three weeks for eight courses. They also administered intramuscular injections of poly-ICLC. The GAAs included EphA2, IL13Rα2 and survivin.

Among 22 evaluable cases, four children had rapidly progressive disease, 14 had stable disease for more than three months, three had sustained partial responses and one had prolonged disease-free status after surgery. ELISPOT analysis, which was completed in seven children, revealed responses in six children: to IL13Rα2 in five cases, EphA2 in three and survivin in three.

“These kids, who, for the most part, have intact and very robust immune systems, seem to mount an immune response against the vaccine very effectively at rates that may be even higher than have been noted in studies in adults,” Pollack said.

Pseudoprogression occurred in some cases and was similar to true tumor progression. For example, one child with a brain stem glioma had transient tumor enlargement and acute neurological deterioration four months after vaccine initiation. However, the tumor later regressed and the patient experienced a sustained partial response. Three other children with brain stem gliomas had symptomatic pseudoprogression, with transient neurological deterioration and tumor enlargement followed by stabilization on decreasing steroid doses.

“This was the first study of its type that examined peptide vaccine therapy for children with brain tumors like this,” Pollack said. “The fact that we’ve seen tumor shrinkage in with very high-risk tumors has been extremely encouraging and somewhat surprising.”

The study was funded by the National Institutes of Health.

Explore further: Novel brain tumor vaccine acts like bloodhound to locate cancer cells

Related Stories

Novel brain tumor vaccine acts like bloodhound to locate cancer cells

January 5, 2012
A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

Lifting the fog: Finding by neuro-oncologist could help eliminate 'chemo brain'

September 29, 2011
After receiving her medical degree in her homeland of Romania, Dr. Daniela Bota came to the U.S. to earn a doctorate in molecular biology to better understand why people develop neurodegenerative diseases such as Alzheimer's.

Scientists find potential benefit of hypericin for recurrent brain tumors

April 11, 2011
Researchers have found that a synthetic version of hypericin, a compound naturally found in St. John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online ...

Recommended for you

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.